Microba Life Sciences (ASX:MAP) said that studies of its MetaPanel gastrointestinal pathogen test found that 40% of inflammatory bowel disease (IBD) patients tested positive for gastrointestinal pathogens, and over 60% of the pathogens would have been missed using standard diagnostic methods, according to a Tuesday statement by the company.
MetaPanel was designed to identify pathogens not detected by conventional tests to help clinicians avoid unnecessary treatments, reduce treatment failures, and minimize the need for surgery, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.